Snapshot

DOI:

Following the research – update on the latest developments, from access site closure, to valve-in-valve transcatheter aortic valve implantation, to drug-coated balloons

It seems every week there is a new trial announced or follow-up data from an ongoing one, or perhaps it is a new technique or device that you’ve heard of and are interested in checking out. You could wait for the national and international meetings. You could wait even longer for an update of one of the specialised guidelines, or you can read it here, twice a month, in our Journal – with specially chosen articles, so you can remain up to date!

Bailout MANTA for transfemoral TAVI

Oliver Dumpies, Mohamed Abdel-Wahab and colleagues evaluate the efficacy and safety of using the MANTA, a large-bore plug-based device, for bailout access site closure after ProGlide failure during transfemoral TAVI. Although safe, operator experience was crucial to successful use of the current-generation device.

Vascular closure algorithm for transfemoral TAVI

Liesbeth Rosseel, Ole De Backer and colleagues describe the novel, stepwise MultiCLOSE vascular closure algorithm, which involves the reinsertion of a 6-8 Fr sheath following an initial closure with one or two suture-based vascular closure devices. The algorithm allows for an easy, safe, efficacious and durable vascular closure after transfemoral TAVI with multiple levels of safety nets, resulting in a major vascular complication rate <1%.

ACURATE vs Evolut for valve-in-valve TAVI

Won-Keun Kim, Tobias Rheude and colleagues compare patients who underwent transfemoral valve-in-valve TAVI for severe structural valve degeneration using either the Evolut R/PRO/PRO+ or the ACURATE neo/neo2 valves. Although procedural outcomes were similar, device success was tied to the true inner diameter dimensions.

Redo-TAVI with ACURATE neo2 in SAPIEN 3

David Meier, Janarthanan Sathananthan and colleagues explore the potential of the ACURATE platform in the treatment of failed balloon-expandable valves. In assessing transcatheter heart valve performance, neoskirt height and expansion of the ACURATE platform inside a SAPIEN 3 – compared to redo-TAVI with a SAPIEN inside a SAPIEN – they found favourable hydrodynamic outcomes and minimal pinwheeling with the ACURATE in SAPIEN combinations.

Biological differences in paclitaxel- and sirolimus-coated balloons

In an animal study comparing the biological and histological drug efficacy of the currently available drug-coated balloons, Kazuki Aihara, Gaku Nakazawa and colleagues demonstrate that paclitaxel-coated balloons might have higher efficacy and lower drug concentrations in the distal skeletal muscles than the MagicTouch sirolimus-coated balloon.

Volume 20 Number 6
Mar 18, 2024
Volume 20 Number 6
View full issue

Suggested by Cory
Trending articles
334.8

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
202.75

State-of-the-Art

10.4244/EIJ-D-21-00089 Jun 11, 2021
Intracoronary optical coherence tomography: state of the art and future directions
Ali ZA et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
42.15

State-of-the-Art

10.4244/EIJ-D-25-00896 Apr 6, 2026
Pretreatment with antiplatelet agents in patients undergoing coronary revascularisation
Kaur G et al
free
33.05

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
27.6

Original Research

10.4244/EIJ-D-25-01370 May 21, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
27.6

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved